Prodromal Psychosis, Prodromal Schizophrenia
Conditions
Keywords
early intervention, social functioning, role functioning, cognition
Brief summary
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.
Detailed description
During the 12-week study, eligible patients are seen 7-9 times by research raters and psychiatrists. These visits include side effect monitoring, scheduled medication increases, and ratings designed to measure subtle improvement of symptoms. Monthly blood and urine samples are collected for safety and substance abuse monitoring, and neuropsychological testing is conducted at the first and last appointments. Participants are compensated for their participation and receive medication and study-related visits at no cost during the trial. Depending on their level of response to the medication, participants may also be eligible for a 3-month extension phase.
Interventions
DRUGaripiprazole
Sponsors
Bristol-Myers Squibb
Northwell Health
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 22 Years
Healthy volunteers
No
Inclusion criteria
* You are between the ages of 13 and 22. * You are English-speaking. * You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder * OR - * You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences. * You meet additional RAP criteria assessed during screening and interview.
Exclusion criteria
* You have a diagnosis of bipolar disorder or major depression with psychotic features. * You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain. * You have past or current substance dependence. * You are currently taking Aripiprazole. * You have taken Aripiprazole in the past. * You are currently taking and responding well to another medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score on attenuated positive symptom scale at 12 weeks | — |
| Score on attenuated negative symptom scale at 12 weeks | — |
| Score on adverse events rating scale at 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Score on social functioning scale at 12 weeks | — |
| Score on academic functioning scale at 12 weeks | — |
| Score on cognitive measures at 12 weeks | — |
Countries
United States
Outcome results
None listed